<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251783</url>
  </required_header>
  <id_info>
    <org_study_id>Metlin&amp;MetlosChildren</org_study_id>
    <nct_id>NCT01251783</nct_id>
  </id_info>
  <brief_title>A Prebiotic Agave Derivated Metlin &amp; Metlos in Infant Formula</brief_title>
  <official_title>Double Blind, Randomized, Controlled Clinical Trial for Evaluate The Efficiency and Safety of a Fiber System From Agave, With Prebiotic Action, Metlin® and Metlos®, Incorporated to an Infant Formula for Term Newborn Babies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Pediatrics, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nekutli S.A. de C.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Pediatrics, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To evaluate the safety; efficacy; bone mineral metabolism &amp; immunity changes of
      the use of Metlin &amp; Metlos added to the Infant Formula Study Design: Randomized, double
      blind, clinical, controlled trial, in 600 full-term infants of 15 ± 7 days randomized to
      recive formula with probiotics + Metlin + Metlos; formula with probiotics + Metlin; Formula
      with probiotics + Metlos; formula only with probiotics or formula without probiotics and
      prebiotics; having a totally breast feed group as control.). Outcomes variables were
      frequency of stools; bowel intolerance manifestations (abdominal distension, flatulency,
      regurgitations, vomiting); report of dermatological problems like eczema; changes on the
      intestinal microbiota; lipids profile (cholesterol, triglycerides, lipoproteins associated to
      cholesterol); anthropomorphic profile and somatic growth ( weight gain, stature, arm mean
      circumference, skin folds); bone mineral metabolism (high-speed bone ultrasonography); and
      changes in the immunity (changes in the concentrations of salivary IgA and the frequency of
      respiratory events suggestive of infection)]. Statistical analysis was made with STATA Ver.
      11.0 for Mac. Safety and efficacy variables, were compared by Chi squared in the case of
      categorical variables or by ANOVA or Kruskall Wallis for the numeric variables. When
      convenient, a covariates adjustment was done by ANOVA or by multiple lineal regressions for
      continuous numerical outcomes or logistic regression for categoric outcomes. In all the
      hypothesis tests the p significant value of &lt;0.05 were used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Metlin &amp; Metlos Aministration in Infant Formula</measure>
    <time_frame>February 2010 to September 2010</time_frame>
    <description>Safety of Metlin &amp; Metlos administration in infant formula was measured by means of the frequency of stools output reported daily by the mother or the keeper (nurse) during the whole study and by the presence gastrointestinal manifestations of intolerance (abdominal distension, flatulency, regurgitations, vomiting), or by the report of eczema type dermatological problems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Administration of Metlin &amp; Metlos in Infant Formula</measure>
    <time_frame>February 2010 to September 2010</time_frame>
    <description>Efficacy of Metlin &amp; Metlos in Infant Formula was measured by means of the change on the intestinal micro flora; changes in the lipids profile (cholesterol, triglycerides, lipoproteins associated to cholesterol); changes in the anthropomorphic profile and somatic growth ( weight gain, stature, arm mean circumference, skin folds); bone mineral metabolism (bone ultrasonography); changes in the immunity (changes in the concentrations of salivary IgA) and reduction of respiratory events suggestive of infection.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Healthy Term Babies</condition>
  <arm_group>
    <arm_group_label>Infant Formula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant Formula without lactobaillus or Metlin or Metlos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fully breast milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group non randomized with fully breast milk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metlin+Metlos+Lactobacillus GG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metlin+Lactobacillus GG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metlos+Lactobacillus GG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus GG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Infant Formula</intervention_name>
    <description>Only Infant Formula without Lactobacillus, Metlin OR Metlos</description>
    <arm_group_label>Infant Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Exclusively breast milk</intervention_name>
    <description>Children non randomized which mothers decided to feed them with exclusively breast milk</description>
    <arm_group_label>Fully breast milk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Metlin+metlos+Lactobacillus GG</intervention_name>
    <description>A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG</description>
    <arm_group_label>Metlin+Metlos+Lactobacillus GG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Metlin + Lactobacillus GG</intervention_name>
    <description>A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG</description>
    <arm_group_label>Metlin+Lactobacillus GG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Metlos + lactobacillus GG</intervention_name>
    <description>A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG</description>
    <arm_group_label>Metlos+Lactobacillus GG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus GG</intervention_name>
    <description>An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos</description>
    <arm_group_label>Lactobacillus GG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy term babies (37 to 42 weeks of gestationl age)

          -  Age 15 ± 7 days at admission

          -  Birth weight &gt; 2,490 g.

          -  Negative history of formula intolerance (only randomized babies)

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Clinical evidence of chronic cardiac, respiratory, gastrointestinal, hematological or
             metabolic disease.

          -  Maternal medical history of diabetes (gestational diabetes was acceptable if the
             infant's birth weight was at or below the percentile 95; or 4153 g or 9 lbs 3 oz for
             girls or 4340 g or 9 lbs 9 oz for boys

          -  Tuberculosis, immunologic deficiency, infection disease or perinatal infections known
             to cause adverse effects in the fetus

          -  Participation in other study

          -  Inability of the father/mother or legal tutor to reed or comprehend the informed
             consent and the symtoms report diary, or

          -  The infant was part of multiple labor (twins, triplets, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Lopez-Vealzquez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Insitute of Pediatrics, Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Gutierrez-Castrellon, MD, MSc, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Pediatrics, Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Pediatric Institute</name>
      <address>
        <city>Mexico city</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Leach JD, Sobolik KD. High dietary intake of prebiotic inulin-type fructans in the prehistoric Chihuahuan Desert. Br J Nutr. 2010 Jun;103(11):1558-61. doi: 10.1017/S0007114510000966. Epub 2010 Apr 26.</citation>
    <PMID>20416127</PMID>
  </reference>
  <reference>
    <citation>Gomez E, Tuohy KM, Gibson GR, Klinder A, Costabile A. In vitro evaluation of the fermentation properties and potential prebiotic activity of Agave fructans. J Appl Microbiol. 2010 Jun;108(6):2114-21. doi: 10.1111/j.1365-2672.2009.04617.x. Epub 2009 Nov 4.</citation>
    <PMID>19941629</PMID>
  </reference>
  <reference>
    <citation>Lopez MG, Mancilla-Margalli NA, Mendoza-Diaz G. Molecular structures of fructans from Agave tequilana Weber var. azul. J Agric Food Chem. 2003 Dec 31;51(27):7835-40.</citation>
    <PMID>14690361</PMID>
  </reference>
  <reference>
    <citation>Grüber C, van Stuijvenberg M, Mosca F, Moro G, Chirico G, Braegger CP, Riedler J, Boehm G, Wahn U; MIPS 1 Working Group. Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants. J Allergy Clin Immunol. 2010 Oct;126(4):791-7. doi: 10.1016/j.jaci.2010.07.022. Epub 2010 Sep 15.</citation>
    <PMID>20832848</PMID>
  </reference>
  <reference>
    <citation>Sazawal S, Dhingra U, Hiremath G, Sarkar A, Dhingra P, Dutta A, Verma P, Menon VP, Black RE. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010 Aug 13;5(8):e12164. doi: 10.1371/journal.pone.0012164.</citation>
    <PMID>20730056</PMID>
  </reference>
  <results_reference>
    <citation>Sabater-Molina M, Larqué E, Torrella F, Zamora S. Dietary fructooligosaccharides and potential benefits on health. J Physiol Biochem. 2009 Sep;65(3):315-28. doi: 10.1007/BF03180584. Review.</citation>
    <PMID>20119826</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>December 1, 2010</last_update_submitted>
  <last_update_submitted_qc>December 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pedro Gutierrez Castrellon</name_title>
    <organization>National Pediatric of Pediatrics, Mexico</organization>
  </responsible_party>
  <keyword>term babies</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

